메뉴 건너뛰기




Volumn 30, Issue 2, 2010, Pages 136-143

Effect of telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: A randomized, double-blind, crossover study in healthy subjects

Author keywords

Drug interaction; Midazolam; Pharmacokinetics; Telavancin

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM; PLACEBO; TELAVANCIN; THRX 651540; UNCLASSIFIED DRUG;

EID: 75849120818     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.136     Document Type: Article
Times cited : (22)

References (19)
  • 1
    • 10744223657 scopus 로고    scopus 로고
    • In vitro activity of TD-6424 against Staphylococcus aureus
    • Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3602-4.
    • (2003) Antimicrob Agents Chemother , vol.47 , pp. 3602-3604
    • Pace, J.L.1    Krause, K.2    Johnston, D.3
  • 2
    • 3042658714 scopus 로고    scopus 로고
    • Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424)
    • Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57:326-36.
    • (2004) J Antibiot (Tokyo) , vol.57 , pp. 326-336
    • Leadbetter, M.R.1    Adams, S.M.2    Bazzini, B.3
  • 3
    • 33845365227 scopus 로고    scopus 로고
    • Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
    • Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:1177-84.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 1177-1184
    • Barcia-Macay, M.1    Lemaire, S.2    Mingeot-Leclercq, M.P.3    Tulkens, P.M.4    Van Bambeke, F.5
  • 4
    • 33748089329 scopus 로고    scopus 로고
    • Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus
    • Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:338-43.
    • (2006) J Antimicrob Chemother , vol.58 , pp. 338-343
    • Leuthner, K.D.1    Cheung, C.M.2    Rybak, M.J.3
  • 5
    • 35948988437 scopus 로고    scopus 로고
    • In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe
    • Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007;51:3420-4.
    • (2007) Antimicrob Agents Chemother , vol.51 , pp. 3420-3424
    • Jansen, W.T.1    Verel, A.2    Verhoef, J.3    Milatovic, D.4
  • 6
    • 2442674119 scopus 로고    scopus 로고
    • Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria
    • King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803.
    • (2004) J Antimicrob Chemother , vol.53 , pp. 797-803
    • King, A.1    Phillips, I.2    Kaniga, K.3
  • 7
    • 2542485522 scopus 로고    scopus 로고
    • In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic grampositive species and Corynebacterium spp
    • Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic grampositive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48:2149-52.
    • (2004) Antimicrob Agents Chemother , vol.48 , pp. 2149-2152
    • Goldstein, E.J.1    Citron, D.M.2    Merriam, C.V.3    Warren, Y.A.4    Tyrrell, K.L.5    Fernandez, H.T.6
  • 8
    • 20044363986 scopus 로고    scopus 로고
    • Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
    • Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 1127-1134
    • Higgins, D.L.1    Chang, R.2    Debabov, D.V.3
  • 9
    • 21144449191 scopus 로고    scopus 로고
    • Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria
    • Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7.
    • (2005) Clin Infect Dis , vol.40 , pp. 1601-1607
    • Stryjewski, M.E.1    O'Riordan, W.D.2    Lau, W.K.3
  • 10
    • 33644637932 scopus 로고    scopus 로고
    • Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study
    • Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7.
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 862-867
    • Stryjewski, M.E.1    Chu, V.H.2    O'Riordan, W.D.3
  • 11
    • 67049094129 scopus 로고    scopus 로고
    • Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: The ATTAIN studies [abstract]
    • Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies [abstract]. Clin Microbiol Infect 2008;14(suppl 7):S14.
    • (2008) Clin Microbiol Infect , vol.14 , Issue.SUPPL. 7
    • Rubinstein, E.1    Corey, G.R.2    Stryjewski, M.E.3
  • 12
    • 43949095864 scopus 로고    scopus 로고
    • Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms
    • Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-93.
    • (2008) Clin Infect Dis , vol.46 , pp. 1683-1693
    • Stryjewski, M.E.1    Graham, D.R.2    Wilson, S.E.3
  • 13
    • 11244316714 scopus 로고    scopus 로고
    • Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
    • Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201.
    • (2005) Antimicrob Agents Chemother , vol.49 , pp. 195-201
    • Shaw, J.P.1    Seroogy, J.2    Kaniga, K.3    Higgins, D.L.4    Kitt, M.5    Barriere, S.6
  • 14
    • 0003979206 scopus 로고    scopus 로고
    • Theravance, Inc, South San Francisco, CA;
    • Theravance, Inc. Data on file. South San Francisco, CA; 2006.
    • (2006) Data on file
  • 15
    • 10744232330 scopus 로고    scopus 로고
    • The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    • Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32.
    • (2003) Drug Metab Dispos , vol.31 , pp. 815-832
    • Bjornsson, T.D.1    Callaghan, J.T.2    Einolf, H.J.3
  • 16
    • 0034807892 scopus 로고    scopus 로고
    • Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - toward a consensus
    • Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 2001;18:1071-80.
    • (2001) Pharm Res , vol.18 , pp. 1071-1080
    • Tucker, G.T.1    Houston, J.B.2    Huang, S.M.3
  • 17
    • 77952585757 scopus 로고    scopus 로고
    • Rockville, MD: U.S. Food and Drug Administration;, Available from, Accessed March 26, 2009
    • Center for Drug Evaluation and Research. Drug development and drug interactions: table of substrates, inhibitors and inducers. Rockville, MD: U.S. Food and Drug Administration; 2006. Available from http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm. Accessed March 26, 2009.
    • (2006) Drug development and drug interactions: Table of substrates, inhibitors and inducers
  • 18
    • 75849155094 scopus 로고    scopus 로고
    • Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products, general considerations. Rockville, MD:, Available from, Accessed March 26
    • Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville, MD: U.S. Food and Drug Administration; 2003. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. Accessed March 26, 2009.
    • (2003)
  • 19
    • 27144556111 scopus 로고    scopus 로고
    • Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
    • Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11:7398-404.
    • (2005) Clin Cancer Res , vol.11 , pp. 7398-7404
    • Lepper, E.R.1    Baker, S.D.2    Permenter, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.